Breast cancer classification according to immunohistochemical markers: Clinicopathologic features and short-term survival analysis in a population-based study from the South of Switzerland

Annals of Oncology

Volumn 20, Issue 4, 2009, Pages 628-635

  Spitale, Alessandra ^a   Mazzola, P ^a   Soldini, D ^a   Mazzucchelli, L ^a   Bordoni, A ^a  

^a INSTITUTE OF PATHOLOGY   (Switzerland)

Author keywords

Cancer registry; Immunohistochemistry; Molecular breast cancer subtypes

Indexed keywords

BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR 2; KI 67 ANTIGEN; TRASTUZUMAB;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CLASSIFICATION; CANCER INVASION; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; CANCER TISSUE; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; POPULATION RESEARCH; POSTMENOPAUSE; PREMENOPAUSE; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; SWITZERLAND;

ADULT; AGED; BREAST NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; POPULATION SURVEILLANCE; PROGNOSIS; SURVIVAL ANALYSIS; SWITZERLAND;

EID: 63549108121     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdn675     Document Type: Article

References (46)

1. Bordoni A, Mazzola P. Cancer incidence in Switzerland, Ticino (1998-2002). In Curado MP, Edwards B, Shin HR et al. (eds): Cancer Incidence in Five Continents. Vol. IX. IARC Scientific Publications No. 160. Lyon: IARC 2007.
2. Ticino Cancer Registry. http://www.ti.ch/DSS/DSP/IstCP/RCT/dati/ default.htm.
3. Perou CM, Sørlie T, Eisen MB et al. Molecular portraits of human breast tumours. Nature 2000; 406(6797): 747-752.
4. Sørlie T, Perou CM, Tibshirani R et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001; 98(19): 10869-10874.
5. Sorlie T, Tibshirani R, Parker J et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003; 100(14): 8418-8423.
6. Sotiriou C, Neo SY, McShane LM et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci USA 2003; 100(18): 10393-10398.
7. Carey LA, Perou CM, Livasy CA et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006; 295(21): 2492-2502.
8. Millikan RC, Newman B, Tse CK et al. Epidemiology of basal-like breast cancer. Breast Cancer Res Treat 2008; 109(1): 123-139.
9. Foulkes WD, Stefansson IM, Chappuis PO et al. Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst 2003; 95(19): 1482-1485.
10. Liu H, Fan Q, Zhang Z et al. Basal-HER2 phenotype shows poorer survival than basal-like phenotype in hormone receptor-negative invasive breast cancers. Hum Pathol 2008; 39(2): 167-174.
11. Tang P, Wang J, Bourne P. Molecular classifications of breast carcinoma with similar terminology and different definitions: Are they the same? Hum Pathol 2008; 39(4): 506-513.
12. Cui X, Schiff R, Arpino G et al. Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy. J Clin Oncol 2005; 23(30): 7721-7735.
13. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: An overview of the randomised trials. Lancet 1998; 351(9114): 1451-1467.
14. Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 2005; 365(9472): 1687-1717.
15. Braga S, dal Lago L, Bernard C et al. Use of trastuzumab for the treatment of early stage breast cancer. Expert Rev Anticancer Ther 2006; 6(8): 1153-1164.
16. Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005; 353(16): 1659-1672.
17. Bauer KR, Brown M, Cress RD et al. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: A population-based study from the California cancer Registry. Cancer 2007; 109(9): 1721-1728.
18. Yang XR, Sherman ME, Rimm DL et al. Differences in risk factors for breast cancer molecular subtypes in a population-based study. Cancer Epidemiol Biomarkers Prev 2007; 16(3): 439-443.
19. Fritz A, Percy C, Jack A et al. International Classification of Diseases for Oncology, 3rd edition. Geneva: World Health Organization 2000.
20. Tavassoli FA, Devilee P. Pathology and Genetics of Tumours of the Breast and Female Genital Organs. Lyon: IARC Press 2003.
21. Jensen OM, Parkin DM, MacLennan R et al. Cancer Registration. Principles and Methods. IARC Scientific Publication No. 95. Lyon: IARC 1991.
22. Tyczynski JE, Démaret E, Parkin DM. Standards and Guidelines for Cancer Registration in Europe. The ENCR recommendations vol. I. IARC Technical Publication No. 40. Lyon: IARC 2003.
23. Ferlay J, Burkhard C, Whelan S, Parkin DM. Check and Conversion Programs for Cancer Registries (IARC/IACR Tools for Cancer Registries). IARC Technical Report No. 42. Lyon: IARC 2005.
24. Parkin DM, Chen VW, Ferlay J et al. Comparability and quality control in cancer registration. IARC Technical Report No. 19. Lyon: IARC 2004.
25. Bullard J, Coleman MP, Robinson D et al. Completeness of cancer registration: A new method for routine use. Br J Cancer 2000; 82(5): 1111-1116.
26. Wolff AC, Hammond ME, Schwartz JN et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007; 25(1): 118-145.
27. Reis-Filho JS, Tutt AN. Triple negative tumours: A critical review. Histopathology 2008; 52(1): 108-118.
28. Nielsen TO, Hsu FD, Jensen K et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004; 10(16): 5367-5374.
29. van de Rijn M, Perou CM, Tibshirani R et al. Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome. Am J Pathol 2002; 161(6): 1991-1996.
30. Abd El-Rehim DM, Pinder SE, Paish CE et al. Expression of luminal and basal cytokeratins in human breast carcinoma. J Pathol 2004; 203(2): 661-671.
31. Dent R, Trudeau M, Pritchard KI et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 2007; 13: 4429-4434.
32. Kreike B, van Kouwenhove M, Horlings H et al. Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas. Breast Cancer Res 2007; 9(5): R65.
33. Da Silva L, Clarke C, Lakhani SR. Demystifying basal-like breast carcinomas. J Clin Pathol 2007; 60(12): 1328-1332.
34. Haffty BG, Yang Q, Reiss M et al. Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol 2006; 24(36): 5652-5657.
35. Pestalozzi B, Castiglione M. Primary breast cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Ann Oncol 2008; 19(2): Ii7-ii10.
36. Bloom HJ, Richardson WW. Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer 1957; 11(3): 359-377.
37. Elston CW. Grading of invasive carcinoma of the breast. In Page DL, Anderson TJ (eds): Diagnostic Histopathology of the Breast. Edinburgh: Churchill Livingstone 1987; 300-311.
38. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. The value of histological grade in breast cancer: Experience from a large study with long-term follow-up. Histopathology 1991; 19(5): 403-410.
39. Greene FL, Page DL, Fleming ID et al. AJCC Cancer Staging Manual, 6th edition. New York: Springer-Verlag 2002.
40. Dratva J, Zemp E, Staedele P et al. Variability of reproductive history across the Swiss SAPALDIA cohort - patterns and main determinants. Ann Hum Biol 2007; 34(4): 437-453.
41. Cantor AB. SAS Survival Analysis Techniques for Medical Research, 2nd edition. Cary, NC: SAS Institute Inc. 2003.
42. Walker GA. Common Statistical Methods for Clinical Research with SAS Examples, 2nd edition. Cary, NC: SAS Institute Inc. 2002.
43. Smith I, Procter M, Gelber RD et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: A randomised controlled trial. Lancet 2007; 369(9555): 29-36.
44. Rakha EA, El-Sayed ME, Green AR et al. Prognostic markers in triple-negative breast cancer. Cancer 2007; 109(1): 25-32.
45. Abdel-Fatah TM, Powe DG, Hodi Z et al. Morphologic and molecular evolutionary pathways of low nuclear grade invasive breast cancers and their putative precursor lesions: Further evidence to support the concept of low nuclear grade breast neoplasia family. Am J Surg Pathol 2008; 32(4): 513-523.
46. Untch M, Gelber RD, Jackisch C et al. Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial. Ann Oncol 2008; 19(6): 1090-1096.